• Record sales orders of $63.4M, up 22% on FY24
• Record revenues of $51.0M, up 3% on FY24
• EBITDA of $2.9M, up 9% on FY24

Compumedics Ltd, a leading global medical device company, has achieved record sales orders of $63 million and record revenues of $51 million for FY25. The company's market strategy is focused on scaling recurring revenues, strengthening global reach, and advancing differentiated technologies across sleep, neuro, and brain research. Key highlights include: - Record sales orders of $63.4M, up 22% on FY24- Record revenues of $51.0M, up 3% on FY24 (up 15% excluding MEG)- EBITDA of $2.9M, up 9% on FY24- Gross margin expanded to 61% (FY24: 52%)- Somfit and SaaS revenues reached $6.7M, now 11% of total revenue (FY24: 9%)- Secured key multi-year agreements, including a $3M p.a. five-year pharmacy-based HST program with Philips in Australia- U.S. sales orders increased 118% YoY to $20.9M, reflecting strong Somfit uptake and U.S. sales team build-out- Signed two four-year distribution agreements in China totalling $24.4M with minimum 10% annual growth commitments

FY26 guidance: - Sales Orders >$75 million- Revenue > $70 million (+37% YoY) - EBITDA $9 million (13% margin)

Compumedics is positioned for accelerated growth in FY26, with strong order momentum and expanding recurring revenue base. Key growth drivers include global expansion of Somfit & Nexus 360 SaaS, execution of MEG backlog and delivery of secured China systems, relaunch of Ez-Dop and advancement of robotic TCD platform, and continued U.S. market penetration across sleep and neuro diagnostics.